Treatment Study Comparing Medium or High Dose Uva-1 Treatment 3x/Week Versus Fluocinonide 0.05% Cream in the Treatment of Morphea.

A Prospective, Open Label Trial of High Dose UVA-1, 3x/Week or Medium Dose UVA-1, 3x/Week vs. Fluocinonide 0.05% Cream Treatment of Morphea

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00812188

Enrollment

Registered

2008-12-22

Start date

2004-11-30

Completion date

2009-11-30

Last updated

2019-02-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Symmetric Limited Morphea

Keywords

Morphea, Plaque morphea, Localized Scleroderma

Brief summary

Compare UVA-1 phototherapy treatment to topical steroid treatment in subjects with morphea.

Interventions

OTHERMedium Dose UVA-1

UVA-1 phototherapy treatment (60 J/cm2) three times per week for 12 weeks.

OTHERHigh Dose UVA-1

High dose (120 J/cm2)UVA-1 phototherapy three times per week for 12 weeks.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 99 Years

Healthy volunteers

Inclusion criteria

* Male and female subjects 18 years of age or older. * Symmetric limited morphea.

Exclusion criteria

* Known sensitivity to fluocinonide 0.05% cream. * Clinical evidence of superinfected skin. * Immunocompromised state (including previously documented HIV). * Generalized Scleroderma. * Previous history of skin cancer. * Non-English speaking subjects.

Design outcomes

Primary

Measure	Time frame
Efficacy of UVA-1 treatment vs. topical steroid.	5 years

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026